What is the equivalent dose of Lantus (insulin glargine) for a patient taking 15 units of Tresiba (insulin degludec)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Converting from Tresiba 15 Units to Lantus

For a patient taking 15 units of Tresiba (insulin degludec), start Lantus (insulin glargine) at 15 units once daily—use a 1:1 unit-for-unit conversion. 1, 2

Conversion Rationale

The standard approach is a direct 1:1 unit conversion when switching between long-acting basal insulins. 1, 2 Both Tresiba and Lantus are long-acting basal insulins designed to provide 24-hour glucose control, though they differ in their pharmacokinetic profiles. 3, 4, 5

Key Pharmacokinetic Differences to Understand

  • Tresiba (insulin degludec) has an ultra-long half-life of 17-21 hours with a duration of action exceeding 42 hours, providing extremely flat and predictable insulin levels. 5

  • Lantus (insulin glargine) has a shorter duration of approximately 24 hours with a peakless profile, though some patients may require twice-daily dosing if coverage is inadequate. 3, 4

  • Despite these pharmacokinetic differences, the glucose-lowering potency per unit is equivalent, justifying the 1:1 conversion. 5

Practical Conversion Protocol

Day 1 of Conversion

  • Give the last dose of Tresiba at the usual time. 1
  • Start Lantus 15 units the following day at your preferred consistent time (morning or evening). 2, 3
  • Continue all other diabetes medications unchanged unless specifically contraindicated. 2

Monitoring Requirements During Transition

  • Check fasting blood glucose daily for the first 2 weeks after conversion. 2
  • Monitor for hypoglycemia, particularly during the first 3-5 days when residual Tresiba activity overlaps with new Lantus dosing. 5
  • Watch for signs of inadequate basal coverage, including fasting glucose >130 mg/dL or significant glucose rise between meals. 2

Dose Titration After Conversion

  • If fasting glucose is 140-179 mg/dL, increase Lantus by 2 units every 3 days. 2
  • If fasting glucose is ≥180 mg/dL, increase Lantus by 4 units every 3 days. 2
  • Target fasting glucose of 80-130 mg/dL. 2
  • If hypoglycemia occurs without clear cause, reduce the dose by 10-20% immediately. 2

Critical Threshold Warning

When Lantus dose exceeds 0.5 units/kg/day (approximately 35-40 units for a 70-80 kg patient) and glucose remains elevated, this signals the need for prandial insulin coverage rather than further basal insulin increases. 2 Signs of "overbasalization" include bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia episodes, and high glucose variability. 2

Special Considerations

Potential Need for Twice-Daily Lantus

Some patients may find that Lantus does not provide full 24-hour coverage, particularly those with type 1 diabetes or high glycemic variability. 6 If fasting glucose is controlled but pre-dinner glucose rises significantly, consider splitting the total daily Lantus dose into two administrations 12 hours apart. 6

Advantages Lost with Conversion

Tresiba's ultra-long duration allows flexible dosing timing (intervals of 8-40 hours between doses), which is lost with Lantus requiring consistent daily timing. 7, 5 However, Lantus has decades of safety data and lower cost in many settings. 3, 4

When NOT to Convert

If the patient is achieving excellent glycemic control on Tresiba 15 units without hypoglycemia, there is no clinical benefit to switching to Lantus. 6 The conversion should only be pursued for cost considerations, formulary restrictions, or patient preference. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Insulin Glargine: a review 8 years after its introduction.

Expert opinion on pharmacotherapy, 2009

Research

Insulin glargine (Lantus).

International journal of clinical practice, 2002

Guideline

Insulin Glargine Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.